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Abstract
Bleeding malignant wounds in palliative care patients can be anxiety-provoking for patients, their caregivers,
and healthcare providers, and can be difficult to manage. We present the case of a 60-year-old man with a
bleeding neck wound due to squamous cell carcinoma of the hypopharynx admitted to our inpatient palliative
care unit. Management of bleeding included local wound care measures and psychosocial support for the patient
and his wife. We review therapeutic approaches to managing bleeding malignant wounds with the aim of
providing clinically useful information.
Introduction
Bleeding associated with malignant wounds can bedifficult to manage in all settings, but particularly in
settings in which goals of care center on comfort and quality of
life. We discuss a challenging case of a patient with a persis-
tent bleeding malignant neck wound arising from a stage IV
supraglottic squamous cell carcinoma.
Case Description
Mr. W., a 60-year-old man, was admitted to our palliative
care unit for profound debility and persistent bleeding of a
malignant neck wound due to stage IV supraglottic squamous
cell carcinoma diagnosed one year prior. Initial treatment
included radiation therapy and laryngectomy with bilateral
neck dissection and flap reconstruction. He subsequently
presented with a rapidly enlarging right pre-auricular mass
and right facial paralysis. A computerized tomography (CT)
scan of the head and neck revealed a large mass extending
from his right styloid process to his right mid-clavicle. Oto-
laryngology (ENT) and Oncology services were not able to
offer further palliative surgery or chemotherapy. There were
no further anticancer treatments available and he was en-
rolled in home hospice.
Mr. W. had been declining rapidly in the two weeks prior to
admission. He was unable to eat or drink due to increased
throat pain and somnolence. His wife requested a transfer to
the inpatient unit for unremitting wound bleeding. The
wound had constant sanguinous oozing interspersed with
episodes of more brisk bleeding. The patient’s wife worried
that her husband might bleed to death in their home.
On admission, physical examination revealed a cachectic
man with a large ulcerated wound along the angle of his jaw
from just below his left ear to his tracheostomy. The inferior
aspect of the wound approached the left clavicle. The wound
had multiple areas of punctuate hemorrhages and required
frequent dressing changes to absorb the bleeding. There was no
significant odor. His tracheostomy secretions were thick and
dark reddish-brown with occasional bright red streaks of blood.
The plan of care focused on aggressive pain management
and wound care as well as psychosocial and spiritual support
of the patient and his wife. To decrease wound bleeding, the
ENT service recommended oxymetazoline spray applied to
the wound and a primary non-occlusive dressing overlaid
with gauze. Wound manipulation was minimized with
dressing changes only after blood was visible through the
dressing. In addition, tracheostomy care was minimized, and
glycopyrrolate was used in an attempt to decrease secretions.
Both his wound and his tracheostomy bleeding slowed down
after minimizing dressing changes to every other day. Mr. W.
had periods of mild delirium throughout his hospitalization,
but otherwise appeared comfortable. He became unrespon-
sive on the fourth day of admission and died comfortably and
without bleeding on the seventh day.
Discussion
Malignant wounds are caused by direct tumor invasion
into the skin due to primary tumor growth or metastatic in-
volvement. Fungating wounds occur fairly commonly in ad-
vanced cancer,1 and one in ten patients with metastatic
disease has cutaneous metastases.2 Cancers that have been
associated with an increased propensity to develop malignant
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wounds include breast cancer, head and neck cancer, and
primary skin cancers.1 Lung, kidney, and colon cancers also
have a high prevalence of fungating wounds.1,3 The majority
of malignant wounds are associated with at least one signif-
icant symptom, including pain, infection, odor, oozing, and
bleeding, as well as consequences due to mass effect such as
airway obstruction or major vessel erosion.1,4 Furthermore,
malignant wounds are a significant source of psychological
and social burden as they can affect self-esteem and sociali-
zation.3,5 They can be a source of spiritual and existential
distress as wound-related symptoms, including odor and
bleeding, can be anxiety-provoking and act as a constant re-
minder of incurable disease and shortened life expectancy.6
Patients often report fear of ‘‘bleeding to death.’’1
Bleeding associated with malignant wounds can pose a
significant challenge to patients, caregivers, and palliative care
providers. Controlling bleeding in malignant wounds can be
difficult due to underlying pathophysiology, and multiple
factors associated with malignancy such as thrombocytopenia,
disseminated intravascular coagulopathy (DIC), and malnu-
trition, which can further increase the risk of bleeding. Wounds
are formed from cancer cells that stimulate angiogenesis. This
new vasculature is abnormal, with haphazard connections and
leaky, dilated vessels5 and has a propensity to ooze and bleed.
Moreover, masses can become necrotic, resulting in further
oozing and odor. The larger lesions are more susceptible to
mechanical irritation and bleeding due to their increased size.
Wound assessment involves characterization of the wound
itself, presence and degree of bleeding, and associated
symptoms, including pain. Potential reversible factors con-
tributing to the patient’s wound-related symptoms should be
sought and pain medication regimen optimized. An under-
standing of the patient’s overall prognosis and goals of care is
essential and will aid in implementing an appropriate plan for
wound care. In addition to assessing the impact of the wound
on the patient’s quality of life, the clinician should assess for
caregiver anxiety and distress related to the wound and
wound care needs. Several nonvalidated tools address wound
severity and clinical manifestations, impact of dressings and
dressing changes on patients, and overall effects of the wound
on patients’ physical, social, and emotional well-being.4,7 To
our knowledge, there are no current validated measures to
assess the risk of bleeding in malignant wounds.
Management
The management of bleeding wounds involves proper
wound care, control of symptoms such as pain and anxiety,
and patient and family support and education. Opioids and
benzodiazepines can be used to control pain and anxiety.3,7,8
In home hospice settings, caregivers should be educated on
how to manage brisk bleeding, in the event this occurs, by
applying steady pressure with dark linens.8
Local wound care
Multiple authors recommend a combination of a non-
adherent layer with an absorptive dressing.9–11 However there
is insufficient evidence as to which dressings offer the best
benefit.12 Soft silicones (e.g., Mepitel and Mepilex dressings);
hydrogels (e.g., Kendall Aquaflo, Medline Derma-Gel);
petroleum jelly gauze; and foam dressings have minimal ad-
herence, while calcium alginate, sucralfate and hydrocolloid
dressings are absorptive and hemostatic. The softer, non-
adherent dressing layer should minimize pain and local trauma
with dressing changes while the absorptive and hemostatic
layer on top should control exudates and bleeding. Dressings
should be long lasting to minimize dressing changes.9–11 For
minimal bleeding, compressive dressings are appropriate. For
brisk bleeding or exudates not controlled with occlusive dress-
ings, management with an ostomy bag has been suggested.13
Topical vasoconstriction and local cauterization can be
achieved through the use of epinephrine, cocaine, and silver
nitrate for minimal local bleeding.8,11 Oxymetazoline, a local
vasoconstrictor and decongestant that works via stimulation of
alpha-adrenergic receptors, can also be utilized for local he-
mostasis, although this off-label use is an area in need of further
study. Oxymetazoline has been used to control epistaxis and to
achieve hemostasis perioperatively in nasal surgery.14–16 In
addition, aerosolized vasopressin has been used for treatment
of hemoptysis and may also be beneficial as a topical vaso-
constrictor.17 Thromboplastin is a natural clotting agent that
comes as a powder and can be used under dressings.18 Su-
cralfate is another readily available paste, and can be applied
directly to wounds to help control widespread oozing.3
While specific dressings can minimize oozing and odor,
bleeding remains a problem especially during dressing chan-
ges. A recent case series of five patients showed good hemo-
stasis after application of Mohs paste, a chemical fixative
containing zinc chloride used for micrographic skin cancer re-
section and first described in 1941. The paste is thought to work
through local chemical infiltration resulting in decreased su-
perficial blood flow to the area.19 The case series used Mohs
paste for hemostasis without resection; bleeding was stopped
after the first application, lasting from three weeks up to three
months. Odor and exudates were also improved. The main
complication was pain while applying the paste.19
Systemic therapy
In malignant fungating wounds, bleeding may be exacer-
bated by coagulopathy from bone marrow suppression or
invasion, poor nutrition, or DIC. Depending on the etiology
and goals of care, patients may benefit from Vitamin K, fresh
frozen plasma, red blood cells, or platelets. Aminocaproic acid
and tranexamic acid are oral synthetic antifibrinolytic
agents.20,21 A case series in 1997 studied the use of aminoca-
proic acid and tranexamic acid for low pressure oozing in the
setting of hemoptysis, hematuria, and fungating wounds. In
this series, 14 of the 16 patients experienced a total cessation of
bleeding. The main side effects of treatment were nausea and
vomiting, and no patients had thrombotic events, a theoretical
risk.20 A more recent study found two thirds of patients with
thrombocytopenic hemorrhage had complete relief of bleed-
ing after administration of aminocaproic acid.21
If radiation therapy to the area has not been exhausted, it can
be considered for tumor bulk reduction. It should be noted,
however, that although radiation therapy as a palliative treat-
ment for bleeding has been studied in hemoptysis, gastrointes-
tinal bleeds, and hematuria, it has been only minimally studied
for bleeding associated with malignant cutaneous wounds.5
Interventional radiologic approaches
Radiologic interventions to control bleeding include
transcatheter embolization of the main tumor arteries or direct
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puncture (transcutaneous) embolization. Both transcatheter
and direct embolization may also help shrink the tumor and
decrease mass effect.22–23 Although these procedures are more
invasive, they may be helpful in controlling brisk bleeding.
Surgery
Large bulky tumors may be amenable to surgical resection
when chemotherapy and radiation options have been ex-
hausted. Surgery can help alleviate mass effect with the goal
of preventing emergencies such as tracheostomy invasion or
threatened carotid rupture. Argon Plasma Coagulation (APC)
is a noncontact electrosurgery under an argon plasma atmo-
sphere that directs energy flow to tissues with low conduc-
tivity (like a bleeding tumor). It is thought to cause dessication
and dissection of tumor with sparing of normal, viable tissue.
In one case series of eight patients with recurrent head and
neck cancer, APC was associated with hemostasis and good
cosmetic outcomes.24
Summary
Our case illustrates management of a bleeding wound in a
patient with terminal cancer. Our patient had a malignant
fungating wound arising from a supraglottic squamous cell
carcinoma. He had constant oozing interspersed with brisk
bleeding from his wound that caused substantial caregiver
anxiety. His wound was successfully managed by applying a
topical vasoconstrictor and minimizing wound manipulation.
The interdisciplinary palliative care team also addressed the
wife’s worries about her husband ‘‘bleeding to death’’ by
providing close monitoring and educating her about their
plan to prevent his suffering in the event of a catastrophic
bleed. In our patient’s case, more invasive means of control-
ling bleeding, such as oral anti-fibrinolytic agents, radiation,
surgery, and embolization procedures were not necessary.
Palliative care clinicians should understand both minimal and
more aggressive options to control bleeding from malignant
fungating wounds.
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